Related references
Note: Only part of the references are listed.MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumabas First-line Chemotherapy in Metastatic Colorectal Cancer
Aparna R. Parikh et al.
CLINICAL CANCER RESEARCH (2019)
Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab
Erik van Dijk et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients
Marc Van den Eynde et al.
CANCER CELL (2018)
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Dominiek Smeets et al.
NATURE COMMUNICATIONS (2018)
A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab
Martin D. Berger et al.
CLINICAL CANCER RESEARCH (2018)
The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers
Christopher I. Amos et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2017)
A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
Manuela Salvucci et al.
CLINICAL CANCER RESEARCH (2017)
Deep intronic mutations and human disease
Rita Vaz-Drago et al.
HUMAN GENETICS (2017)
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients
Mariantonietta Di Salvatore et al.
ONCOTARGET (2017)
Polymorphisms in VEGF, eNOS, COX-2, and IL-8 as predictive markers of response to bevacizumab.
L. lo Giudice et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials
M. D. Berger et al.
ANNALS OF ONCOLOGY (2017)
Colorectal cancer statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative
Johannes Betge et al.
DIGESTION (2016)
MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The Ensembl Variant Effect Predictor
William McLaren et al.
GENOME BIOLOGY (2016)
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
Y. Sunakawa et al.
ANNALS OF ONCOLOGY (2015)
Prediction of colorectal cancer diagnosis based oncirculating plasma proteins
Silvia Surinova et al.
EMBO MOLECULAR MEDICINE (2015)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini et al.
LANCET ONCOLOGY (2015)
Single-Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Pathway and Outcomes of Patients Treated with First-Line Cytotoxic Chemotherapy Combined with Bevacizumab for Advanced Colorectal Cancer
Byeong Seok Sohn et al.
ONCOLOGY (2014)
Targeting ER stress induced apoptosis and inflammation in cancer
Tom Verfaillie et al.
CANCER LETTERS (2013)
Markers of Response for the Antiangiogenic Agent Bevacizumab
Diether Lambrechts et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab
Fotios Loupakis et al.
PLOS ONE (2013)
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy
A. Pohl et al.
PHARMACOGENOMICS JOURNAL (2013)
Sarcalumenin plays a critical role in age-related cardiac dysfunction due to decreases in SERCA2a expression and activity
Qibin Jiao et al.
CELL CALCIUM (2012)
The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer Results from the Nordic ACT trial
Torben Frostrup Hansen et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2012)
Autolytic Proteolysis within the Function to Find Domain (FIIND) Is Required for NLRP1 Inflammasome Activity
Joshua N. Finger et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
Diether Lambrechts et al.
LANCET ONCOLOGY (2012)
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
Fotios Loupakis et al.
BMC CANCER (2011)
Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer
Armin Gerger et al.
CLINICAL CANCER RESEARCH (2011)
Single Nucleotide Polymorphism Analysis and Outcome in Advanced-stage Cancer Patients Treated With Bevacizumab
D. Lambrechts et al.
EUROPEAN JOURNAL OF CANCER (2011)
Regression shrinkage and selection via the lasso: a retrospective
Robert Tibshirani
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2011)
A framework for variation discovery and genotyping using next-generation DNA sequencing data
Mark A. DePristo et al.
NATURE GENETICS (2011)
AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)
Y. Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Fast and accurate short read alignment with Burrows-Wheeler transform
Heng Li et al.
BIOINFORMATICS (2009)
Adverse effects of anticancer agents that target the VEGF pathway
Helen X. Chen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab
Anne M. Schultheis et al.
CLINICAL CANCER RESEARCH (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
J. Tol et al.
ANNALS OF ONCOLOGY (2008)
Sarcalumenin alleviates stress-induced cardiac dysfunction by improving Ca2+ handling of the sarcoplasmic reticulum
Miei Shimura et al.
CARDIOVASCULAR RESEARCH (2008)
Polymorphisms of KDR gene are associated with coronary heart disease
Yibo Wang et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Bcl-2 and Bcl-XL regulate proinf lammatory caspase-1 activation by interaction with NALP1
Jean-Marie Bruey et al.
CELL (2007)
Regularization and variable selection via the elastic net
H Zou et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
SIFT: predicting amino acid changes that affect protein function
PC Ng et al.
NUCLEIC ACIDS RESEARCH (2003)
A novel enhancer of the Apaf1 apoptosome involved in cytochrome c-dependent caspase activation and apoptosis
ZL Chu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Prediction of deleterious human alleles
S Sunyaev et al.
HUMAN MOLECULAR GENETICS (2001)
Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families
J Hull et al.
THORAX (2000)
Share Paper
